Pelvic organ prolapse — structured SAQ (15 marks)

(a) POP-Q stage and compartments (3 marks)

One mark for the correct stage, one for the compartments, one for the justification against the hymen. ^[1]

• Stage II. Stage II is the most distal portion of the prolapse lying between 1 cm above and 1 cm below the hymen (at or within 1 cm of the hymen). With Ba and C both at zero (exactly at the hymen), this is Stage II.^[1]
• Compartments involved: anterior (Ba 0 = cystocele) and apical (C 0 = uterine descent). Both the anterior and apical compartments have failed.
• Justification: the hymen is the fixed reference at zero; points above it are negative and points below are positive. Stage I is more than 1 cm above the hymen; Stage III is more than 1 cm below the hymen but not to complete eversion; Stage IV is essentially complete procidentia.

(b) Management ladder (4 marks)

One mark per rung, with the trial evidence named for the PFMT rung. ^[14]

• Observation and lifestyle — weight, smoking and chronic constipation are the modifiable targets, but this woman is symptomatic, so this is adjunct only.
• Pelvic floor muscle training (PFMT) — supervised, individualised, first-line for symptomatic mild-to-moderate prolapse; the International Urogynecology Consultation (Bø 2022) gives high-level evidence from 11 RCTs to recommend PFMT as first-line, improving stage by about one stage.^[14] PREVPROL (Hagen 2017) showed one-to-one PFMT reduced prolapse symptoms at 2 years (mean POP Symptom Score 3.2 vs 4.2, adjusted mean difference minus 1.01).^[7]
• Vaginal pessary — a ring with support (or a Gellhorn for higher stage) is an excellent first-line option for this postmenopausal woman; add topical vaginal oestrogen to optimise the epithelium and reduce ulceration.
• Surgery — Stage II to IV symptomatic prolapse with apical support as the priority; because she has apical descent (point C at the hymen), the apex must be suspended (cross-reference sacrospinous fixation, uterosacral suspension or sacrocolpopexy), not an anterior repair alone.

(c) Occult stress incontinence and OPUS (4 marks)

One mark for the rationale, two for the OPUS numbers, one for the decision framing. ^[12]

• Rationale: reducing the prolapse unkinks the urethra and can unmask occult stress urinary incontinence; a continent woman can return after prolapse surgery "cured of the lump but now leaking" if she is not screened.^[12]
• OPUS (NEJM 2012): in continent women undergoing vaginal prolapse surgery, a prophylactic midurethral sling reduced urinary incontinence at 12 months (27.3% vs 43.0%, p = 0.002), number needed to treat 6.3 — but with higher bladder perforation (6.7% vs 0%), UTI (31.0% vs 18.3%), major bleeding (3.1% vs 0%) and incomplete emptying at 6 weeks (3.7% vs 0%).^[12]
• Decision: a shared decision about which adverse event this individual is willing to risk; for a woman not sexually active and with voiding symptoms already, the threshold for a sling is individualised.

(d) Transvaginal mesh regulatory position (4 marks)

Two marks for the Australian position, one for the international context, one for consent. ^[15]

• Australia: transvaginal mesh products for pelvic organ prolapse were removed from the Australian Register of Therapeutic Goods effective 4 January 2018, and all urogynaecological mesh was subsequently reclassified as Class III (high-risk) devices. This applies to transvaginal mesh for prolapse — not to midurethral slings and not to sacrocolpopexy mesh, which remain in use.^[15]
• International context: the US FDA ordered manufacturers to stop selling transvaginal mesh for POP in 2019; the UK Cumberlege review ("First Do No Harm", 2020) criticised informed consent and recommended specialist centres for those harmed.
• Consent implications: if any mesh-augmented procedure is contemplated (e.g. sacrocolpopexy for apical repair), discuss mesh exposure, erosion into bladder or bowel, contraction with chronic pain and dyspareunia, and the need for possible revision, with documented informed consent.